Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

Clinical trial NCT07398599 · RECRUITING

Trial details

NCT number: NCT07398599
Sponsor: Second Affiliated Hospital of Nanchang University
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Leptomeningeal Metastasis Lung Neoplasms, Non-Small Cell Lung Cancer

Start date: 2026-02-15
Primary completion: 2027-12-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.